News stories about Biostar Pharmaceuticals (NASDAQ:BSPM) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biostar Pharmaceuticals earned a news impact score of 0.05 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.9717611136429 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
TRADEMARK VIOLATION WARNING: “Biostar Pharmaceuticals (BSPM) Receives News Sentiment Rating of 0.05” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2017/11/01/biostar-pharmaceuticals-bspm-receives-news-sentiment-rating-of-0-05.html.
Biostar Pharmaceuticals Company Profile
Biostar Pharmaceuticals, Inc (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co, Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China).
What are top analysts saying about Biostar Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biostar Pharmaceuticals Inc. and related companies.